UsAgainstAlzheimer’s Applauds Positive News on Alzheimer’s Drug Aducanumab
Statement from George Vradenburg on the announcement by Biogen and Eisai of plans to seek regulatory approval in early 2020 by the Food and Drug Administration (FDA) for aducanumab, an investigational treatment for early Alzheimer’s disease.
New Study Highlights Need for Healthcare Providers to Engage Alzheimer’s Caregivers
A new study from UsAgainstAlzheimer's and Mayo Clinic spotlights the often-overlooked need for family caregivers of people with Alzheimer’s disease to be more engaged by physicians during medical appointments with their loved ones.
A road map for including Latinos and African Americans in Alzheimer’s research
Alzheimer’s is the only leading cause of death with no current effective treatment or cure. The limited inclusion of communities of color in research will only worsen the outlook, though the success of efforts bubbling up across the country could help us keep pace.
Four former U.S. Surgeons General: Dementia is our top public health crisis
Former U.S. Surgeons General Drs. Richard Carmona, Joycelyn Elders, Antonia Novello & David Satcher call dementia top public health crisis, urge for an annual brain health check-up
More than 180 Health and Alzheimer’s Groups Urge U.S. Task Force to Revise Stance and Encourage Cognitive Screenings
The U.S. Preventive Services Task Force (USPSTF), which makes recommendations about preventive clinical services contended in a draft recommendation that there is “insufficient” evidence to warrant doctors conducting cognitive screening for older adults. Public comments on the task force’s recommendations are due today.
UsAgainstAlzheimer’s Warns of Setback to Prevention and Care
Cleveland.com Article
A Letter from Our Chairman
UsAgainstAlzheimer’s Brain Health Partnership has issued a Call to Action white paper outlining recommendations for building a better system of care to promote brain health and fight back against Alzheimer’s.
UsAgainstAlzheimer’s Welcomes Eli Lilly Report of Positive Phase III Trial
UsAgainstAlzheimer’s Chairman George Vradenburg issued the following statement regarding the report by Eli Lilly and Company and Avid Radiopharmaceuticals (a subsidiary of Eli Lilly) that flortaucipir, a Positron Emission Tomography imaging
UsAgainstAlzheimer’s Applauds Eisai and Biogen for their Progress Toward a Disease-Modifying Drug
UsAgainstAlzheimer’s Chairman George Vradenburg today issued the following statement regarding the report today by Eisai and Biogen at the Alzheimer’s Association International Conference (AAIC) that their Alzheimer’s Drug BAN2401 demonstrated
The upcoming documentary, “Remembering Gene Wilder” His Life, Legacy and Battle with Alzheimer’s Disease is centered around Gene’s incredible life and subsequent diagnosis with Alzheimer’s disease. Neurologist, Dr. Michael Rafii
The A-LIST transforms the stories of more than 8,000 people living with Alzheimer’s or other dementias into evidence-based insights by providing unique, rapid-response, self-reported data through virtual surveys on what matters most on a wide range of Alzheimer’s-related topics. The A-LIST offers a powerful and validating voice for those living with Alzheimer’s and those caring for them, and a pathway to help expand treatments and accelerate toward a cure.
